| MLČOCH, Tomáš, Barbora DECKER, Eva ORNSTOVÁ, Kateřina CHADIMOVÁ, Jana BARTÁKOVÁ a Tomáš DOLEŽAL. Cost-effectiveness analysis of parenteral methotrexate for the treatment of Crohn’s disease in the Czech Republic. In ISPOR Europe 2018, Barcelona. 2018. ISSN 1098-3015. Dostupné z: https://dx.doi.org/10.1016/j.jval.2018.09.865. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1852607,
author = {Mlčoch, Tomáš and Decker, Barbora and Ornstová, Eva and Chadimová, Kateřina and Bartáková, Jana and Doležal, Tomáš},
booktitle = {ISPOR Europe 2018, Barcelona},
doi = {http://dx.doi.org/10.1016/j.jval.2018.09.865},
title = {Cost-effectiveness analysis of parenteral methotrexate for the treatment of Crohn’s disease in the Czech Republic},
url = {https://www.valueinhealthjournal.com/article/S1098-3015(18)34167-6/fulltext},
year = {2018}
}
TY - CONF
ID - 1852607
AU - Mlčoch, Tomáš - Decker, Barbora - Ornstová, Eva - Chadimová, Kateřina - Bartáková, Jana - Doležal, Tomáš
PY - 2018
TI - Cost-effectiveness analysis of parenteral methotrexate for the treatment of Crohn’s disease in the Czech Republic
UR - https://www.valueinhealthjournal.com/article/S1098-3015(18)34167-6/fulltext
N2 - Over a three-year time horizon, MTX yields additional 0.06 QALYs (1.92 vs. 1.86) at the additional total cost of €761 (€2263 vs. €1503) compared with hdCS, with the incremental cost-effectiveness ratio of €13,077/QALY. PSA showed that probability of MTX to be cost-effective was 99.89% at the WTP. OWSA and SA confirmed the robustness of the base-case result with all one-way changes and scenarios deeply below WTP.
ER -
MLČOCH, Tomáš, Barbora DECKER, Eva ORNSTOVÁ, Kateřina CHADIMOVÁ, Jana BARTÁKOVÁ a Tomáš DOLEŽAL. Cost-effectiveness analysis of parenteral methotrexate for the treatment of Crohn’s disease in the Czech Republic. In \textit{ISPOR Europe 2018, Barcelona}. 2018. ISSN~1098-3015. Dostupné z: https://dx.doi.org/10.1016/j.jval.2018.09.865.
|
